Literature DB >> 31204367

Public-Access Defibrillation and Survival of Out-of-Hospital Cardiac Arrest in Public vs. Residential Locations in Japan.

Takeyuki Kiguchi1, Kosuke Kiyohara2, Tetsuhisa Kitamura3, Chika Nishiyama4, Daisuke Kobayashi1, Satoe Okabayashi1, Tomonari Shimamoto1, Tasuku Matsuyama5, Takashi Kawamura1, Taku Iwami1.   

Abstract

BACKGROUND: This study assessed whether the dissemination of public-access defibrillation (PAD) at the population level is associated with an increase in neurologically favorable outcomes among patients experiencing ventricular fibrillation (VF) in public vs. residential locations in Japan.Methods and 
Results: We enrolled adult patients with bystander-witnessed VF between 2013 and 2015. The primary outcome measure was 1-month neurologically favorable outcome defined by cerebral performance category 1 or 2. The number of survivors with neurologically favorable outcome attributed to PAD after VF arrest was estimated by location of arrest. A total of 16,252 adult patients with bystander-witnessed VF arrest were analyzed. In public locations, 29.3% (2,334/7,973) of out-of-hospital cardiac arrest (OHCA) patients received PAD, whereas 1.1% (89/8,279) of OHCA patients received PAD in residential locations. OHCA patients with PAD had significantly better neurological outcomes compared with those without PAD in public locations (51.8% vs. 25.5%, P<0.001), whereas there were no significant differences in neurologically favorable outcome between patients with or without PAD in residential locations (22.5% vs. 18.6%, P=0.357). The total number of patients with neurologically favorable outcomes attributed to PAD was estimated at 615 in public locations, but only 3 in residential locations.
CONCLUSIONS: In Japan, when compared with residential locations, PAD works more successfully in public locations for adults with bystander-witnessed VF arrest.

Entities:  

Keywords:  Automated external defibrillator; Cardiopulmonary resuscitation; Out-of-hospital cardiac arrest; Public-access defibrillation; Ventricular fibrillation

Year:  2019        PMID: 31204367     DOI: 10.1253/circj.CJ-19-0065

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  Bystander-witnessed cardiopulmonary resuscitation by nonfamily is associated with neurologically favorable survival after out-of-hospital cardiac arrest in Miyazaki City District.

Authors:  Toshihiro Tsuruda; Takaaki Hamahata; George J Endo; Yuki Tsuruda; Koichi Kaikita
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

2.  Alert system-supported lay defibrillation and basic life-support for cardiac arrest at home.

Authors:  Remy Stieglis; Jolande A Zijlstra; Frank Riedijk; Martin Smeekes; Wim E van der Worp; Jan G P Tijssen; Aeilko H Zwinderman; Marieke T Blom; Rudolph W Koster
Journal:  Eur Heart J       Date:  2022-04-14       Impact factor: 29.983

3.  Adult Basic Life Support: International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.

Authors:  Theresa M Olasveengen; Mary E Mancini; Gavin D Perkins; Suzanne Avis; Steven Brooks; Maaret Castrén; Sung Phil Chung; Julie Considine; Keith Couper; Raffo Escalante; Tetsuo Hatanaka; Kevin K C Hung; Peter Kudenchuk; Swee Han Lim; Chika Nishiyama; Giuseppe Ristagno; Federico Semeraro; Christopher M Smith; Michael A Smyth; Christian Vaillancourt; Jerry P Nolan; Mary Fran Hazinski; Peter T Morley
Journal:  Resuscitation       Date:  2020-10-21       Impact factor: 5.262

4.  Sustaining improvement of dispatcher-assisted cardiopulmonary resuscitation for out-of-hospital cardiac arrest patients in Japan: An observational study.

Authors:  R Sagisaka; K Nakagawa; M Kayanuma; S Tanaka; H Takahashi; T Komine; H Tanaka
Journal:  Resusc Plus       Date:  2020-06-27

5.  Increasing the shockable rhythm and survival rate by dispatcher-assisted cardiopulmonary resuscitation in Japan.

Authors:  Minoru Kayanuma; Ryo Sagisaka; Hideharu Tanaka; Shota Tanaka
Journal:  Resusc Plus       Date:  2021-04-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.